Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
PRIMARY OBJECTIVE:
I. To overcome a clinical access issue that would otherwise block patients from reimbursement of a new cancer therapy, and therefore block or significantly delay their care.
OUTLINE:
Patients receive gallium Ga 68 gozetotide intravenously (IV) and then undergo a positron emission tomography (PET)/computed tomography (CT) scan throughout the trial.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
An adult male patient who is actively under the care of a medical oncology, radiation oncology or urology physician at Mayo Clinic
An adult male patient who is deemed eligible (or potentially/likely eligible) for PSMA-targeted radionuclide therapy by a nuclear medicine physician or Radiologist in the nuclear medicine therapy practice, or by the Prostate Theranostic Tumor Board (PTuB)
* Eligibility will be documented in the medical record by the clinical practice
* It is acceptable for the patient to be eligible for PSMA-targeted radionuclide therapy in all regards except for having completed a PSMA-targeted PET scan showing PSMA-positive prostate cancer
* It is acceptable for a patient to be potentially eligible for therapy, but have a relative contraindication, such as a minor laboratory abnormality, and be on the list for discussion at the PTuB in the future
An adult male patient who has not received a 68Ga-PSMA-11 PET/CT or PET/magnetic resonance (MR), or for whom a repeat 68Ga-PSMA-11 PET/CT exam is needed per the clinical practice to ensure eligibility
An adult male patient who does not otherwise have access to a reimbursable clinical 68Ga-PSMA-11 PET scan
An adult above the ages of 18
You may not be if
A patient who is unable to consent per Mayo guidelines
A patient who is unable to lay still, or otherwise successfully complete the imaging exam
Clareo Health | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
